DTC telehealth — direct-to-consumer telehealth — is the model in which the patient is the buyer, purchasing a visit directly from a website rather than through an employer, insurer, or hospital. Typical offerings are urgent-care visits, dermatology consults, and condition-specific programs such as hair-loss treatment or contraception. Because the patient pays out of pocket and chooses the service themselves, the product is shaped above all by conversion and retention.
That commercial reality dominates the design. The mechanics that matter are onboarding in minutes, frictionless card payments, and fast matching to an available clinician — anything that loses the buyer before they reach care is a direct revenue problem. To move quickly, DTC products often defer or skip the integrations that institutional telehealth treats as mandatory: EHR (electronic health record) integration and insurance billing are frequently out of scope, at least early on.
The critical point for a product or compliance team is that none of this reduces the regulatory burden. From the very first visit the product is handling protected health information (PHI) under HIPAA, must obtain valid informed consent, must verify identity to an appropriate level, and must respect state medical-licensure rules — a clinician generally must be licensed in the state where the patient is located, which constrains who can serve which patients. Prescribing adds further obligations, including electronic prescribing of controlled substances (EPCS) requirements where relevant. The common pitfall is letting the fast, consumer-grade front end create the impression that DTC is "lighter" on compliance; in fact the same core obligations apply, just without the institutional scaffolding that a hospital deployment provides.
